Cure My Disease

Don't miss your cure!

 Log in / Sign up

Extra ablation target may cut AF recurrence in persistent cases

NCT ID NCT06929897

Disease control Sponsor: Ewha Womans University Mokdong Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This trial tests whether adding posterior wall isolation to standard pulmonary vein isolation reduces atrial fibrillation recurrence in people with persistent AF. About 482 adults aged 20 to 80 will be randomly assigned to one of the two procedures using pulsed-field energy. Participants will be followed for 12 months to check for any return of abnormal heart rhythms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pulmonary vein isolation with or without posterior wall isolation using pulsed-field ablation
What this could lead to
If successful, adding posterior wall isolation could become a standard approach to lower atrial fibrillation recurrence in patients with persistent AF.
What could go wrong
This is a single-center trial, and results may not apply to all patients. Adding extra ablation could increase complication risks without clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 482 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 20 to 80 years who are candidates for catheter ablation for persistent atrial fibrillation * Patients eligible for catheter ablation according to existing clinical guidelines * Those without clinically significant structural heart disease (e.g., severe mitral regurgitation) * Those without contraindications to anticoagulation therapy Exclusion Criteria: * Atrial fibrillation associated with severe congenital heart disease or structural heart disease * Patients with contraindications to general anesthesia or sedation for the procedure * History of prior cardiac surgery (e.g., Maze procedure, coronary artery bypass grafting) * History of atrial fibrillation catheter ablation within the past 12 months * Patients with severe left ventricular dysfunction (left ventricular ejection fraction \<30%) * Patients with active internal bleeding * Patients with contraindications to anticoagulation therapy and antiarrhythmic drugs * Valvular atrial fibrillation (e.g., mitral stenosis \> grade 2, mechanical valve, prior mitral valve repair) * Patients with severe comorbid conditions * Patients with an expected survival of less than one year * Patients with drug or alcohol addiction * Pregnant or breastfeeding women * Any other conditions deemed by the investigator to make the patient unsuitable for study participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation (AF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation persistent atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation (AF)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ewha Womans University Mokdong Hospitoal

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.